Gujarat Themis Biosyn

₹383.95As of Sun 8 Nov 2026, 12:00 UTC

NSE:GUJTHEMHealthcare

Country India

PE (Fwd) 76.30

TSR 10Y CAGR —

Div yield 0.17%

ROE —

Drug Manufacturers (Specialty & Generic)

Beta (5Y) 0.64

PE TTM 89.62

TSR TTM (17.31%)

Mkt cap ₹49.00B

ROIC —

SE Grade™

Value

Quality

Moat

—

1Y Price

Reference

₹424

10.43%

(81.46%)

Price above Reference Value

TTM

FYE 31 Mar INR

FY2017

FY2018

FY2019

FY2020

FY2021

FY2022

FY2023

FY2024

FY2025

FY2026

FY2027E

Trend

10Y

Peers

1.658

Revenue₹B

—

1.149

1.484

1.698

1.508

1.658

1.801

9.62%

9.96

Revenue growth%

—

29.19

14.45

(11.20)

9.96

8.62

12.20

—

64.85

Gross margin%

—

84.22

61.36

59.52

60.66

64.85

64.14

61.36

37.83

Operating margin%

—

49.22

48.47

44.27

42.66

37.83

37.81

44.27

28.15

Net margin%

—

37.98

39.07

34.84

32.34

28.15

28.19

34.84

89.62

P/E ratio (avg)x

—

62.24

86.19

82.41

74.22

—

66.69

EV/EBITx

—

47.19

64.14

61.44

55.66

—

FCF yield (avg)%

—

FCF margin%

—

FCF / Net incomex

—

ROIC%

—

Return on equity%

—

Return on assets%

—

4.28

EPS₹

—

4.00

5.32

5.43

4.48

4.28

4.66

1.71%

—

(4.29)

EPS growth%

—

32.88

2.06

(17.56)

(4.29)

8.75

(1.11)

—

Bookvalue per sh₹

—

FCF per share₹

—

0.67

Dividend per sh₹

—

0.80

0.72

1.00

0.67

(4.34%)

—

0.17

Div yield (avg)%

—

0.24

0.18

0.21

—

15.65

Payout ratio%

—

19.98

13.53

18.42

14.97

15.65

14.44

15.65

109.0

Shares (diluted)M

—

109.0

◌109.0

—

Buyback yield%

—

◌—

—

D/E ratiox

—

41.84

Enterprise value₹B

—

30.36

40.23

41.84

32.53%

—

LT debt₹M

—

Peers (US$532.4M)

Cap (US$)

IOL Chemicals and…

575.6M

26.66x

Orchid Pharma Limited

552.2M

149.0x

Morepen Laboratories…

536.8M

26.74x

Tibet Weixinkang…

534.0M

18.71x

Capital

TTM

10Y

Leveragex

—

EBIT/Intx

24.15

276.3

Own earn%

—

Sh yield%

0.17

0.09

Owners

Insiders/Inst%

3.34

4.04

Short interest%

—

SBC / revenue%

—

Record

10Y

Profitable years

5/5

Revenue growth years

3/4

EPS growth years

2/4

Dividend streakyrs

Op margin range%

38–49

$1 testx

—

Incr. ROIC%

—

Gujarat Themis Biosyn Limited engages in the manufacture of pharmaceuticals, medicinal chemicals, and active pharmaceutical ingredients in India and internationally. The company offers bulk drugs on job work basis in India.

Growth vs revenue

Latest

Trend

4Y CAGR

Rel growth

Revenue

₹1.658B

9.62%

1.00×

Cost of revenue

₹582.8M

33.91%

2.23×

Operating expenses

₹448.1M

2.75%

0.77×

Revenue by region

No breakdown available

Reinvestment returns

n/m

Trend

Reinvestment rate

n/m

Return on capital

n/m

Spread over hurdle

n/m